Intellia Therapeutics
Pioneer in CRISPR/Cas9-based gene editing therapeutics, developing in vivo and ex vivo treatments for genetic diseases, cancer, and autoimmune conditions. Publicly traded on NASDAQ (NTLA).
Notes
Intellia Therapeutics is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics for serious genetic diseases. Founded in 2014 by CRISPR pioneer Jennifer Doudna and others, Intellia has emerged as one of the leading clinical-stage CRISPR therapy companies.
The company develops both in vivo (direct delivery to patients) and ex vivo (edited cells returned to patients) approaches. Intellia's lead program NTLA-2001 for transthyretin amyloidosis (ATTR) achieved groundbreaking clinical results, demonstrating that CRISPR gene editing can work safely and effectively directly in patients.
Intellia went public on NASDAQ (ticker: NTLA) in 2016 and has established partnerships with Regeneron and Novartis to advance its pipeline.
Team
- John Leonard, M.D. - CEO
- LinkedIn: linkedin.com/in/johnleonard
- Jennifer Doudna, Ph.D. - Co-founder (Nobel Prize winner for CRISPR)
- Experienced leadership team in gene therapy and drug development
Additional Research Findings
- Founded in 2014, headquartered in Cambridge, Massachusetts
- Public company on NASDAQ (ticker: NTLA) since 2016
- Market cap varies significantly with clinical results
- Co-founded by Nobel laureate Jennifer Doudna
- Lead program NTLA-2001 for transthyretin amyloidosis
- Pioneering in vivo CRISPR therapeutics
- Backed by Atlas Venture and other major investors
- Partnerships with Regeneron and Novartis
- Multiple programs in clinical development
- Key competitor to Editas Medicine and CRISPR Therapeutics
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Atlas Venture | Cambridge, USA | biotech-focused | seedseries-a+1 | 1 |